loading
Ultragenyx Pharmaceutical Inc stock is traded at $51.15, with a volume of 569.85K. It is down -0.12% in the last 24 hours and down -5.19% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$51.06
Open:
$50.09
24h Volume:
569.85K
Relative Volume:
0.87
Market Cap:
$4.69B
Revenue:
$481.30M
Net Income/Loss:
$-585.12M
P/E Ratio:
-5.7023
EPS:
-8.97
Net Cash Flow:
$-492.48M
1W Performance:
-3.41%
1M Performance:
-5.19%
6M Performance:
+19.29%
1Y Performance:
+31.34%
1-Day Range:
Value
$49.89
$51.20
1-Week Range:
Value
$49.84
$53.20
52-Week Range:
Value
$34.06
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Name
Ultragenyx Pharmaceutical Inc
Name
Phone
415-483-8800
Name
Address
60 LEVERONI COURT, NOVATO, CA
Name
Employee
1,276
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
RARE's Discussions on Twitter

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-08-23 Initiated Wells Fargo Overweight
Jun-14-23 Resumed Credit Suisse Outperform
Jun-06-23 Upgrade Evercore ISI In-line → Outperform
Apr-26-23 Initiated Cantor Fitzgerald Overweight
Jan-18-23 Resumed Canaccord Genuity Buy
Dec-30-22 Resumed H.C. Wainwright Buy
Nov-03-22 Upgrade Robert W. Baird Neutral → Outperform
Oct-13-22 Upgrade Guggenheim Neutral → Buy
Aug-01-22 Downgrade Evercore ISI Outperform → In-line
Mar-16-22 Upgrade Credit Suisse Neutral → Outperform
Feb-11-22 Upgrade JP Morgan Neutral → Overweight
Sep-30-21 Initiated H.C. Wainwright Buy
Aug-19-21 Initiated UBS Sell
Jul-15-21 Initiated Guggenheim Neutral
Jun-29-21 Upgrade BofA Securities Neutral → Buy
Jun-04-21 Resumed Robert W. Baird Neutral
May-06-21 Upgrade Citigroup Neutral → Buy
May-06-21 Upgrade Evercore ISI In-line → Outperform
Apr-26-21 Resumed Credit Suisse Neutral
Mar-02-21 Resumed Stifel Buy
Feb-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-07-20 Downgrade Wedbush Outperform → Neutral
Nov-24-20 Resumed Evercore ISI In-line
Nov-12-20 Downgrade BofA Securities Buy → Neutral
Aug-02-19 Resumed Wedbush Outperform
Mar-27-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Feb-22-19 Resumed Raymond James Outperform
Jan-02-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18 Upgrade Citigroup Sell → Neutral
Sep-10-18 Initiated Morgan Stanley Equal-Weight
Jun-21-18 Downgrade Credit Suisse Outperform → Neutral
May-11-18 Upgrade Barclays Equal Weight → Overweight
May-10-18 Initiated Goldman Neutral
Apr-18-18 Upgrade SunTrust Hold → Buy
Mar-22-18 Resumed Piper Jaffray Overweight
Feb-21-18 Reiterated Stifel Buy
Jan-22-18 Upgrade Evercore ISI In-line → Outperform
Jan-18-18 Initiated Credit Suisse Outperform
Dec-05-17 Reiterated Barclays Equal Weight
Dec-04-17 Upgrade Jefferies Hold → Buy
Sep-14-17 Upgrade Wedbush Neutral → Outperform
View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

pulisher
03:45 AM

Wealth Enhancement Advisory Services LLC Purchases 14,394 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

03:45 AM
pulisher
Nov 04, 2024

A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga

Nov 04, 2024
pulisher
Nov 03, 2024

Trend Tracker for (RARE) - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 03, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 02, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Trimmed by abrdn plc - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq

Oct 31, 2024
pulisher
Oct 31, 2024

10,904 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Pallas Capital Advisors LLC - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - GlobeNewswire

Oct 29, 2024
pulisher
Oct 26, 2024

Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $85.08 - MarketBeat

Oct 26, 2024
pulisher
Oct 24, 2024

How To Trade (RARE) - Stock Traders Daily

Oct 24, 2024
pulisher
Oct 23, 2024

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year - Yahoo Finance

Oct 23, 2024
pulisher
Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance

Oct 22, 2024
pulisher
Oct 22, 2024

Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical - Benzinga

Oct 21, 2024
pulisher
Oct 21, 2024

TD Cowen Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $73.00 - MarketBeat

Oct 21, 2024
pulisher
Oct 20, 2024

Ultragenyx Pharmaceutical's (NASDAQ:RARE) investors will be pleased with their favorable 70% return over the last year - Simply Wall St

Oct 20, 2024
pulisher
Oct 18, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 18, 2024
pulisher
Oct 17, 2024

Cwm LLC Buys 21,111 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Oct 17, 2024
pulisher
Oct 13, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Sees Significant Decline in Short Interest - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells $393,853.40 in Stock - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Ultragenyx CFO sells shares worth over $390k By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 11, 2024

Ultragenyx CFO sells shares worth over $390k - Investing.com

Oct 11, 2024
pulisher
Oct 10, 2024

RARE's Wilson Disease Candidate Betters Standard Therapy in Study - MSN

Oct 10, 2024
pulisher
Oct 10, 2024

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag - MSN

Oct 10, 2024
pulisher
Oct 09, 2024

Osteogenesis Imperfecta Treatment Market: Global Type, - openPR

Oct 09, 2024
pulisher
Oct 08, 2024

Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN

Oct 08, 2024
pulisher
Oct 08, 2024

Squarepoint Ops LLC Trims Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Ultragenyx gains FDA breakthrough status for OI drug - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

FDA grants breakthrough therapy status to Ultragenyx's osteogenesis imperfecta drug - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Ultragenyx gains FDA breakthrough status for OI drug By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

Ultragenyx Pharmaceutical's Bone Disease Drug Gets FDA's Breakthrough Therapy Designation - MarketWatch

Oct 07, 2024
pulisher
Oct 06, 2024

AQR Capital Management LLC Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Ultragenyx stock rated Outperform as analyst sees $900M peak sales potential - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

RARE's Wilson Disease Candidate Betters Standard Therapy In Study - Barchart

Oct 04, 2024
pulisher
Oct 04, 2024

Ultragenyx tweaks gene therapy dosing to dial up efficacy after seeing signs of activity - Fierce Biotech

Oct 04, 2024
pulisher
Oct 04, 2024

The Manufacturers Life Insurance Company Cuts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Oct 04, 2024

Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Ultragenyx Pharmaceutical Inc Stock (RARE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
KAKKIS EMIL D
President & CEO
Sep 03 '24
Sale
55.85
20,000
1,117,000
2,223,985
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Sep 03 '24
Sale
56.19
91
5,113
41,551
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):